Synonym
NCGC 84; NCGC84; NCGC-84; ML 154; ML154; ML-154; NCGC00185684.
IUPAC/Chemical Name
3-(Diphenylphosphinothioyl)-2-methyl-1-[(2E)-3-phenyl-2-propen-1-yl]imidazo[1,2-a]pyridinium bromide
InChi Key
CJAQCMBWGUOBIX-ZUQRMPMESA-M
InChi Code
InChI=1S/C29H26N2PS.BrH/c1-24-29(32(33,26-17-7-3-8-18-26)27-19-9-4-10-20-27)31-22-12-11-21-28(31)30(24)23-13-16-25-14-5-2-6-15-25;/h2-22H,23H2,1H3;1H/q+1;/p-1/b16-13+;
SMILES Code
CC1=C(P(C2=CC=CC=C2)(C3=CC=CC=C3)=S)[N+]4=CC=CC=C4N1C/C=C/C5=CC=CC=C5.[Br-]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
ML 154 is a potent neuropeptide S receptor (NPSR) antagonist (pA2 = 9.98).
In vitro activity:
NCGC84 inhibited NPS-induced ERK phosphorylation in a concentration-dependent manner, and the resulting IC50 value, 9.3 nm, is 2.3- and 3.9-fold more potent than the cAMP and intracellular calcium response, respectively (Fig. 5A). The inhibition of NPS-induced ERK phosphorylation by NCGC84 was confirmed by Western blot analysis (Fig. 5B).
Reference: J Neurosci. 2013 Jun 12;33(24):10132-42. https://pubmed.ncbi.nlm.nih.gov/23761908/
In vivo activity:
In vivo, systemic NCGC00185684 blocks alcohol-induced ERK-phosphorylation in the rat central amygdala, a region involved in regulation of alcohol intake. NCGC00185684 also decreases operant alcohol self-administration, and lowers motivation for alcohol reward as measured using progressive ratio responding.
Reference: J Neurosci. 2013 Jun 12;33(24):10132-42. https://pubmed.ncbi.nlm.nih.gov/23761908/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
54.6 |
100.00 |
| Ethanol |
27.3 |
50.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
545.48
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Thorsell A, Tapocik JD, Liu K, Zook M, Bell L, Flanigan M, Patnaik S, Marugan J, Damadzic R, Dehdashti SJ, Schwandt ML, Southall N, Austin CP, Eskay R, Ciccocioppo R, Zheng W, Heilig M. A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats. J Neurosci. 2013 Jun 12;33(24):10132-42. doi: 10.1523/JNEUROSCI.4742-12.2013. PMID: 23761908; PMCID: PMC3682378.
In vitro protocol:
Thorsell A, Tapocik JD, Liu K, Zook M, Bell L, Flanigan M, Patnaik S, Marugan J, Damadzic R, Dehdashti SJ, Schwandt ML, Southall N, Austin CP, Eskay R, Ciccocioppo R, Zheng W, Heilig M. A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats. J Neurosci. 2013 Jun 12;33(24):10132-42. doi: 10.1523/JNEUROSCI.4742-12.2013. PMID: 23761908; PMCID: PMC3682378.
In vivo protocol:
Thorsell A, Tapocik JD, Liu K, Zook M, Bell L, Flanigan M, Patnaik S, Marugan J, Damadzic R, Dehdashti SJ, Schwandt ML, Southall N, Austin CP, Eskay R, Ciccocioppo R, Zheng W, Heilig M. A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats. J Neurosci. 2013 Jun 12;33(24):10132-42. doi: 10.1523/JNEUROSCI.4742-12.2013. PMID: 23761908; PMCID: PMC3682378.
1: Thorsell A, Tapocik JD, Liu K, Zook M, Bell L, Flanigan M, Patnaik S, Marugan J, Damadzic R, Dehdashti SJ, Schwandt ML, Southall N, Austin CP, Eskay R, Ciccocioppo R, Zheng W, Heilig M. A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats. J Neurosci. 2013 Jun 12;33(24):10132-42. doi: 10.1523/JNEUROSCI.4742-12.2013. PubMed PMID: 23761908; PubMed Central PMCID: PMC3682378.
